Pain related to intravitreal injections for age-related macular degeneration: a qualitative study of the perspectives of patients and practitioners

被引:2
|
作者
Yiallouridou, Christina [1 ]
Acton, Jennifer H. [1 ]
Banerjee, Sanjiv [2 ]
Waterman, Heather [3 ]
Wood, Ashley [1 ]
机构
[1] Cardiff Univ, Sch Optometry & Vis Sci, Cardiff, Wales
[2] Cardiff & Vale Univ Hlth Board, Ophthalmol, Cardiff, Wales
[3] Cardiff Univ, Healthcare Sci, Cardiff, Wales
来源
BMJ OPEN | 2023年 / 13卷 / 08期
关键词
QUALITATIVE RESEARCH; PAIN MANAGEMENT; OPHTHALMOLOGY; NEEDLE SIZE; RANIBIZUMAB; EXPERIENCES; ANXIETY; ANESTHESIA; FEAR;
D O I
10.1136/bmjopen-2022-069625
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectivesOcular pain is a commonly reported finding in the intravitreal injection procedure, but post-injection experiences and patient adherence to treatment remain underexplored. We therefore aimed to identify key variations in the intravitreal injection procedure that may influence pain, and to gain insights into the post-injection experience and treatment adherence from the perspective of patients and practitioners. DesignQualitative semistructured interview study using reflexive thematic analysis of transcripts. SettingHospital Eye Clinic in Wales, UK. Interviews were conducted between May and September 2019. ParticipantsPurposive sample of patients aged & GE;50 years with neovascular age-related macular degeneration and no other retinal pathology who had received at least six intravitreal injections, and practitioners including ophthalmologists, registered nurses and optometrists who performed intravitreal injections at the research site. ResultsData saturation was reached with 21 interviews: 14 patients and 7 practitioners. Three main themes were identified from the analysis: fear of losing eyesight and treatment anxiety influence patient adherence to treatment, variability in pain experience during treatment, and post-injection experience and impact on patient recovery. To reassure patients feeling apprehensive about the injections, practitioners promoted safety and trust, and used techniques to manage anxiety. Key variations that may influence pain identified were application of antiseptic or anaesthetic, injecting methods and communication. During injection, patients reported a dull-aching and sharp pain, contrary to practitioners' perspective of feeling a 'pressure'. Patients described prolonged soreness and irritation of up to 36 hours post-injection affecting their sleep and recovery. ConclusionEstablishing rapport supported patients to recognise the necessity of ongoing treatment to prevent sight loss; however, inadequate pain management led to undesirable outcomes. Practitioners should use pain assessment tools during and immediately after injection and provide ongoing consistent information to help patients manage pain at home.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration
    Park, Dae Hyun
    Sun, Hae Jung
    Lee, Sung Jin
    INTERNATIONAL OPHTHALMOLOGY, 2017, 37 (05) : 1205 - 1214
  • [32] Cost of Ranibizumab Port Delivery System vs Intravitreal Injections for Patients With Neovascular Age-Related Macular Degeneration
    Sood, Shefali
    Mandell, Jordan
    Watane, Arjun
    Friedman, Scott
    Parikh, Ravi
    JAMA OPHTHALMOLOGY, 2022, 140 (07) : 716 - 723
  • [33] Changes in cone-driven functions after intravitreal aflibercept injections in patients with age-related macular degeneration
    Nishimura, Tomoharu
    Machida, Shigeki
    Hara, Yuji
    DOCUMENTA OPHTHALMOLOGICA, 2020, 141 (02) : 137 - 147
  • [34] Changes in cone-driven functions after intravitreal aflibercept injections in patients with age-related macular degeneration
    Tomoharu Nishimura
    Shigeki Machida
    Yuji Hara
    Documenta Ophthalmologica, 2020, 141 : 137 - 147
  • [35] Do Intravitreal Ranibizumab Injections for Wet Age-Related Macular Degeneration Affect the Vitreomacular Interface?
    Sreekantam, S.
    Gibson, J. M.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [36] Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration
    Daien, Vincent
    Vuong Nguyen
    Essex, Rohan W.
    Morlet, Nigel
    Barthelmes, Daniel
    Gillies, Mark C.
    OPHTHALMOLOGY, 2018, 125 (01) : 66 - 74
  • [37] Repeated intravitreal injections of triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration
    Jonas, JB
    Kreissig, I
    Degenring, R
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2002, 240 (10) : 872 - 873
  • [38] AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION The ARI2 Study
    Blanco-Garavito, Rocio
    Jung, Camille
    Uzzan, Joel
    Quaranta-ElMaftouhi, Maddalena
    Coscas, Florence
    Sahel, Jose
    Korobelnik, Jean-Francois
    Bechet, Stephane
    Querques, Giuseppe
    Souied, Eric H.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 (12): : 2285 - 2292
  • [39] Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration
    Jonas, JB
    Akkoyun, I
    Budde, WM
    Kreissig, I
    Degenring, RF
    ARCHIVES OF OPHTHALMOLOGY, 2004, 122 (02) : 218 - 222
  • [40] Intravitreal triamcinolone acetonide in exudative age-related macular degeneration
    Danis, RP
    Ciulla, TA
    Pratt, LM
    Anliker, W
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2000, 20 (03): : 244 - 250